Last reviewed · How we verify
Intravenous Fentanyl 25 mcg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravenous Fentanyl 25 mcg (Intravenous Fentanyl 25 mcg) — Alexza Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravenous Fentanyl 25 mcg TARGET | Intravenous Fentanyl 25 mcg | Alexza Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravenous Fentanyl 25 mcg CI watch — RSS
- Intravenous Fentanyl 25 mcg CI watch — Atom
- Intravenous Fentanyl 25 mcg CI watch — JSON
- Intravenous Fentanyl 25 mcg alone — RSS
Cite this brief
Drug Landscape (2026). Intravenous Fentanyl 25 mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-fentanyl-25-mcg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab